NeuroSense plans to apply to Canada’s regulators for early marketing approval of the oral therapy, supported by a Phase 2b ...

In an ALS study, growth factor FGF4 reduced the activity of star-shaped cells called astrocytes but did not stop motor ...

The new patent covers Neurosense's formulation of PrimeC, a fixed-dose combo of an approved antibiotic and anti-inflammatory.

Changes in the production of several immune proteins at the time of an ALS diagnosis were linked to disease progression in ...

Avextra plans a Phase 2 trial in Italy to test a cannabis-based oral medicine to ease symptoms in ALS and other ...

Neuvivo has filed an application with the U.S. Food and Drug Administration (FDA) requesting the approval of its ...

Differences in human tears in ALS can distinguish bulbar-onset disease from spinal-onset ALS, making this a possible ...

Researchers have developed a type of gene therapy that selectively targets diseased nerve cells in ALS while leaving healthy ...

Modality.AI and Target ALS are partnering on a clinical study of AI as a way to assess changes in speech and motor function ...

Living with ALS is easier with six tried-and-tested everyday habits, columnist Dagmar Munn has found. Among them: dressing well.

ProJenX teamed with Unlearn to create digital twins of ALS patients as a placebo group in open-label extension of Phase 1 ...